MX2012013703A - Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). - Google Patents

Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2012013703A
MX2012013703A MX2012013703A MX2012013703A MX2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A MX 2012013703 A MX2012013703 A MX 2012013703A
Authority
MX
Mexico
Prior art keywords
modified
betulinic acid
maturation inhibitors
acid derivatives
hiv maturation
Prior art date
Application number
MX2012013703A
Other languages
English (en)
Inventor
Sing-Yuen Sit
Alicia Regueiro-Ren
Nicholas A Meanwell
Jacob Swidorski
Zheng Liu
Jie Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2012013703A publication Critical patent/MX2012013703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se definen compuestos que tienen propiedades farmacológicas y bioafección, sus composiciones farmacéuticas y métodos de uso. En particular, ácido C3-betulínico modificado y otros derivados de productos naturales relacionados estructuralmente que poseen una actividad antiviral única se proporcionan como inhibidores de la maduración del VIH. Estos compuestos son útiles para el tratamiento del VIH y el SIDA.
MX2012013703A 2010-06-04 2011-06-02 Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih). MX2012013703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35133810P 2010-06-04 2010-06-04
PCT/US2011/038879 WO2011153315A1 (en) 2010-06-04 2011-06-02 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (1)

Publication Number Publication Date
MX2012013703A true MX2012013703A (es) 2012-12-17

Family

ID=44627236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013703A MX2012013703A (es) 2010-06-04 2011-06-02 Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).

Country Status (12)

Country Link
US (1) US8754068B2 (es)
EP (1) EP2576585B8 (es)
JP (1) JP5752789B2 (es)
CN (1) CN103038245B (es)
AR (1) AR081637A1 (es)
BR (1) BR112012030818A2 (es)
CA (1) CA2801487C (es)
EA (1) EA022393B1 (es)
ES (1) ES2612452T3 (es)
MX (1) MX2012013703A (es)
TW (1) TW201201793A (es)
WO (1) WO2011153315A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
WO2011146768A1 (en) 2010-05-20 2011-11-24 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
PL2670764T3 (pl) * 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
AU2012268036B2 (en) 2011-06-06 2017-04-06 THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS Methods of inhibiting muscle atrophy
WO2013043778A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
SG11201506445PA (en) * 2013-02-25 2015-09-29 Bristol Myers Squibb Co C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
SI3129392T1 (sl) 2014-04-11 2020-11-30 VIIV Healthcare UK(No.4) Limited Triterpenoidi z inhibitorno aktivnostjo maturacije HIV-a, substituirani na položaju 3 z nearomatskim obročem, ki nosi haloalkilni substituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
CN107250153A (zh) * 2014-11-14 2017-10-13 Viiv保健英国第五有限公司 氧代羽扇豆烯衍生物
EP3218388A1 (en) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
KR20170092580A (ko) * 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 연장된 베툴린산 유사체
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
RU2018112958A (ru) 2015-09-24 2019-10-28 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Соединения с ингибирующей созревание ВИЧ активностью
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190307776A1 (en) 2016-06-30 2019-10-10 Viiv Healthcare Uk (No. 5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
WO2018002848A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
AU762404B2 (en) * 1998-03-02 2003-06-26 Panacos Pharmaceuticals, Inc. Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2004028455A2 (en) * 2002-09-26 2004-04-08 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
JP4722031B2 (ja) * 2003-02-11 2011-07-13 ノベリックス・ファーマシューティカルズ・インコーポレイテッド 腫瘍増殖を阻害するための医薬
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) * 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
JP2009527563A (ja) * 2006-02-21 2009-07-30 アキリオン ファーマシューティカルズ，インコーポレーテッド ウイルス感染症を治療するのに有用な置換タラキサスタン
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) * 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
US20090062243A1 (en) * 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
RS55631B1 (sr) * 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
CN102883608A (zh) * 2010-02-11 2013-01-16 葛兰素史密丝克莱恩有限责任公司 白桦脂醇衍生物

Also Published As

Publication number Publication date
EA201270780A1 (ru) 2013-04-30
JP5752789B2 (ja) 2015-07-22
BR112012030818A2 (pt) 2019-09-24
US20120142707A1 (en) 2012-06-07
CN103038245B (zh) 2015-03-25
CA2801487C (en) 2017-12-05
ES2612452T3 (es) 2017-05-17
US8754068B2 (en) 2014-06-17
CN103038245A (zh) 2013-04-10
AR081637A1 (es) 2012-10-10
EP2576585A1 (en) 2013-04-10
EA022393B1 (ru) 2015-12-30
WO2011153315A1 (en) 2011-12-08
JP2013527242A (ja) 2013-06-27
EP2576585B1 (en) 2016-10-12
TW201201793A (en) 2012-01-16
CA2801487A1 (en) 2011-12-08
EP2576585B8 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
MX2012013703A (es) Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
TN2013000321A1 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2013008359A (es) Aminas de c-28 de derivados de acido betulinico modificado de c-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2014013089A (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2013004491A (es) Boronatos como inhibidores de arginasa.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
EA025518B9 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MY199668A (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
PH12012501389A1 (en) Hedgehog inhibitors
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
MX2013008536A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana.
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration